← Leaderboards
Lisa R Gerak
University Of Texas Hlth Sci Ctr San Ant
$4,086,471
Attributed
$4,086,471
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $553.5K · FY2005–19$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
Funding mix
By agency
NIH$4,086,471 · 4
By mechanism
R01$3,251,502 · 2
R21$834,969 · 2
Top collaborators
No co-investigators on record.
Most similar at University Of Texas Hlth Sci Ctr San Ant
Same institution · by research overlap
- Wouter Koek$4,458,124
- William P Clarke$10,604,907
- Alan L Peterson$719,180
- Charles Lee Bowden$6,118,203
- Jeffrey W Kiel$3,253,745
Others in their field
Top investigators on “Pharmaceutical Preparations”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David Heimbrook · Leidos Biomedical Research, Inc.$266,816,120
- Leonard Freedman · Leidos Biomedical Research, Inc.$240,520,687
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$196,976,947
- Lawrence Corey · Fred Hutchinson Cancer Center$196,976,947
Research focus
Pharmaceutical PreparationsProceduresWithdrawalChronicDoseBenzodiazepinesDependencePreventSiteDrug DiscriminationPregnanoloneReceptorEthanolBehavioralLeadStimulusAlcohol Withdrawal SyndromeEffectivenessMonkeysSleeplessnessInsightAnxietyGrantOpioid
Grant awards (18)
Preclinical assessment of buprenorphine/lorcaserin mixtures for the treatment of opioid abuse$190,625
R21 · FY2019 · DA · contact PI
Preclinical assessment of buprenorphine/lorcaserin mixtures for the treatment of opioid abuse$228,750
R21 · FY2018 · DA · contact PI
Reinforcing effects of opioid/benzodiazepine mixtures$188,718
R21 · FY2016 · DA · contact PI
Reinforcing effects of opioid/benzodiazepine mixtures$226,876
R21 · FY2015 · DA · contact PI
Behavioral Effects of Neuroactive Steroids$216,068
R01 · FY2014 · DA · contact PI
Behavioral Effects of Neuroactive Steroids$207,425
R01 · FY2013 · DA · contact PI
Discriminative Effects of Benzodiazepine Withdrawal$324,101
R01 · FY2012 · DA · contact PI
Behavioral Effects of Neuroactive Steroids$216,068
R01 · FY2012 · DA · contact PI
Discriminative Effects of Benzodiazepine Withdrawal$324,101
R01 · FY2011 · DA · contact PI
Behavioral Effects of Neuroactive Steroids$216,068
R01 · FY2011 · DA · contact PI
Discriminative Effects of Benzodiazepine Withdrawal$330,784
R01 · FY2010 · DA · contact PI
Behavioral Effects of Neuroactive Steroids$222,750
R01 · FY2010 · DA · contact PI
Discriminative Effects of Benzodiazepine Withdrawal$333,281
R01 · FY2009 · DA · contact PI
Discriminative Effects of Benzodiazepine Withdrawal$333,000
R01 · FY2008 · DA · contact PI
Behavioral Effects of Neuroactive Steroids$173,044
R01 · FY2007 · DA · contact PI
Behavioral Effects of Neuroactive Steroids$178,212
R01 · FY2006 · DA · contact PI
Behavioral Effects of Neuroactive Steroids$154,773
R01 · FY2005 · DA
Behavioral Effects of Neuroactive Steroids$21,827
R01 · FY2005 · DA